Topical vancomycin applied on closure of the sternotomy wound does not prevent high levels of systemic vancomycin

European Journal of Cardio-thoracic Surgery

Volumn 23, Issue 5, 2003, Pages 765-770

  Desmond, Joel ^a   Lovering, Andy ^a   Harle, Chris ^a   Djorevic, Tatiana ^a   Millner, Russell ^a  

^a BLACKPOOL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

Coronary artery bypass; Drug resistance; Mediastinitis; Staphylococcus aureus; Thoracic surgery; Vancomycin

Indexed keywords

VANCOMYCIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORONARY ARTERY BYPASS GRAFT; DRAIN; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG URINE LEVEL; ELECTIVE SURGERY; FEMALE; HUMAN; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; STERNOTOMY; SURGICAL WOUND; WOUND CLOSURE;

ADMINISTRATION, TOPICAL; AGED; ANALYSIS OF VARIANCE; ANTI-BACTERIAL AGENTS; COHORT STUDIES; CORONARY ARTERY BYPASS; FEMALE; HUMANS; MALE; MEDIASTINITIS; MIDDLE AGED; POSTOPERATIVE CARE; VANCOMYCIN;

EID: 0038674327     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1010-7940(03)00033-2     Document Type: Article

References (20)

1. Loop F.D., Lytle B.W., Cosgrove D.M. Sternal wound complications after isolated coronary artery bypass grafting: early and late mortality, morbidity and cost of care. Ann Surg. 49:1990;179-187.
2. Grossi E.A., Culliford A.T., Krieger K.H. A survey of 77 major infectious complications of median sternotomy: a review of 7,949 consecutive operative procedures. Ann Thorac Surg. 40:(214):1985;223.
3. Ivert T., Lindblom D., Sahni J., Eldh J. Management of deep sternal wound infection after cardiac surgery - Hanuman syndrome. Scand J Cardiovasc Surg. 25:1991;111-117.
4. Ottino G., Paulis R.D., Pansini S. Major sternal wound infection after open heart surgery: a multivariate analysis of risk factors in 2,579 consecutive operative procedures. J Infect Dis. 44:(173):1987;179.
5. Serry C., Bleck P.C., Javid H. Sternal wound complications: management and results. J Thorac Cardiovasc Surg. 80:1980;861-867.
6. Vander Salm T.J., Okike O.N., Pasque M.K., Pezzella A.T., Lew R., Traina V., Mathieu R. Reduction of sternal infection by application of topical vancomycin. J Thorac Cardiovasc Surg. 98:1989;618-622.
7. El Oakley R.M., Wright J.E. Post-operative mediastinitis: classification and management. Ann Thorac Surg. 61:1996;1030-1036.
8. Aldaz A., Ortega A., Idoate A., Giraldez J., Brugarolas A. Effects of hepatic function on vancomycin pharmacokinetics in patients with cancer. Ther Drug Monit. 22:2000;250-257.
9. Golper T.A., Noonan H.M., Elzinga L., Gilbert D., Brummett R., Anderson J.L., Bennett W.M. Vancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human subjects. Clin Pharmacol Ther. 43:1988;565-570.
10. Sym D., Smith C., Meenan G., Lehrer M. Fluorescence polarization immunoassay: can it result in an overestimation of vancomycin in patients not suffering from renal failure? Ther Drug Monit. 23:2001;441-444.
11. White L.O., MacGowan A.P., Lovering A.M., Reeves D.S., Ryder D., Holt D.S. Assay of trough serum gentamicin concentrations by fluorescence polarization immunoassay. J Antimicrob Chemother. 33:1994;1068-1070.
12. Ely Lilly And Company Limited. Manufacturers of Vancomycin Hydrochloride as brand name Vanococin. Kingsclere Road, Basingstoke, RG21 6XA. 2002.
13. El Oakley R.M., Nimer K.A., Bukhari E. Is the use of topical vancomycin to prevent mediastinitis after cardiac surgery justified? J Thorac Cardiovasc Surg. 119:(1):2000;190-191.
14. Pasic M., Carrel T., Opravil M., Mihaljevic T., von Segesser L., Turina M. Systemic absorption after local intracolonic vancomycin in pseudomembranous colitis. Lancet. 342:1993;443.
15. Krivoy N., Yanovsky B., Kophit A., Zaher A., Bar-El Y., Adler Z., Gaitini L., Milo S. Vancomycin sequestration during cardiopulmonary bypass surgery. J Infect. 45:2002;90-95.
16. Sieradzki K., Roberts R.B., Haber S.W., Tomaasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med. 340:1999;517-523.
17. Smith T.L., Pearson M.L., Wilcox K.R. Emergence of vancomycin resistance in methicillin-resistant Staphylococcus aureus. N Engl J Med. 340:1999;493-501.
18. Hiramatsu K., Kanaki H., Yabuta K., Oguri T., Tenover F.C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 40:1997;135-136.
19. US Centre for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin - United States. MMWR Morb Mortal Wkly Rep. 51:(26):2002;565-567.
20. Pearson H. 'Superbug' hurdles key drug barrier. Nature. 418:(6897):2002;469.